Press Releases
Media Library
Social Media
Analyst Coverage
Annual and Interim Reports
Annual General Meeting
Conflict Minerals Disclosure
Debt Investors
Dividend
Email Alerts
Events
Financial Highlights
Investor News
Our Strategy
Quarterly Results and Presentations
Recent Acquisitions
Shareholder Information
Stock Information
WHO WE ARE
Our Story
Rare Champions
Areas of Focus
Responsibility
Leadership
How We Operate
PATIENTS
Patient Resources
Patient Services
Patient Advocacy
Charitable Access Program
Scholarships
R&D
Our R&D Strategy
EDUCATIONAL GRANTS
Science & Innovation
Investigator Initiated Research (IIR)
Pipeline
Clinical Trials
Collaborations
PRODUCTS
Product List
Manufacturing
Postmarketing Commitments
CAREERS
Search & Apply
Diversity & Inclusion
Culture & Values
Growing Your Career
Benefits
Early Talent Programs
Work Life Balance
Employee Profiles
Rule 2.9 announcement
CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks
FDA Advisory Committee Recommends Approval of Shire’s Prucalopride (SHP555) for Chronic Idiopathic Constipation
Shire to announce third quarter 2018 results
Rule 2.9 Announcement
Shires Participation at NHF Meeting
Director/PDMR Shareholding
Form 8 (DD) - Susan Kilsby
Form 8 (DD) - Steven Gillis
Form 8 (DD) - Sara Mathew
Form 8 (DD) - Olivier Bohuon
Form 8 (DD) - Ian Clark
LOAD MORE
Learn more
We make decisions that put patients first.
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.